Evidence map›Paper›PMID 37950060›Full record

ArticleSkeletal radiology2024

Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.

Patrick Debs, Allan Belzberg, Jaishri Blakeley, Laura Fayad, Shannon Langmead, Emily Little, Carlos Romo, Krista Schatz, Bronwyn Slobogean, Shivani Ahlawat

Abstract read
PubMed Publisher
In one paragraph

Article in Skeletal radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. [Progress and prospects in diagnosis and treatment of neurofibromatosis type 1].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2024
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Patrick DebsThe Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, JHOC 3014, Baltimore, MD, 21287, USA.
Allan BelzbergDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jaishri BlakeleyDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Laura FayadThe Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, JHOC 3014, Baltimore, MD, 21287, USA.
Shannon LangmeadDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Emily LittleComprehensive Neurofibromatosis Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Carlos RomoDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Krista SchatzMcKusick-Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bronwyn SlobogeanDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shivani AhlawatThe Russell H. Morgan Department of Radiology & Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, JHOC 3014, Baltimore, MD, 21287, USA. sahlawa1@jhmi.edu.ORCID http://orcid.org/0000-0003-4437-5237

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the role of weekly neurofibromatosis (NF) multi-disciplinary conferences (MDC) on the diagnostic and therapeutic plan for patients with NF type 1 (NF1) and schwannomatosis (SWN). MATERIALS AND

methodsThis retrospective study reviewed patients with confirmed or suspected NF1 and SWN discussed in weekly MDC from March to July 2021. Demographic data collected included patient age, sex, pre-conference and post-conference diagnosis, radiological studies reviewed, and provider specialties in attendance. Outcomes reported included changes in imaging interpretation and treatment plans, changes in post-conference diagnosis relative to pre-conference diagnosis, and time to completion of the recommended change in treatment.

resultsData from 17 MDC "pre-conference" lists included 75 patients (38 female, 37 males, mean age (years): 38 (range: 6-80)) with NF1 (52%, 39/75) and SWN (36%, 27/75) discussed over a total of 91 case reviews. 18.7% (14/75) of all patients had NF2-related SWN, and 17.3% (13/75) of all patients had non-NF2 SWN. The MDC led to changes in imaging interpretation in 18.7% and changes in patient management in 74.7% (diagnostic testing (n = 52), surgical plan (n = 24), medical treatment (n = 9), clinical trial status (n = 4), and radiation treatment (n = 1)) of cases. Among patients for whom a change in management was recorded, 91% (62/68) completed at least one recommendation (mean time to completion (days): 41.4 (range: 0-278)).

conclusionWeekly MDC changes the diagnostic and therapeutic management of the majority of patients discussed (74.7%) and promotes a high adherence rate to recommendations (91%).

Indexed as

NeurilemmomaNeurofibromatosesNeurofibromatosis 1Neurofibromatosis 2Skin NeoplasmsFemaleHumansMaleRetrospective StudiesTertiary Health CareMulti-disciplinary conferenceMulti-disciplinary tumor boardNeurofibromatosisSchwannomatosis

Identifiers

PMID37950060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.